Corticosteroid Responsiveness Following Mepolizumab in Severe Eosinophilic Asthma-A Randomized, Placebo-Controlled Crossover Trial (MAPLE). (2022)

First Author: Yang F
Attributed to:  United Kingdom Refractory Asthma Stratification Programme (RASP-UK) funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.jaip.2022.06.050

PubMed Identifier: 35863669

Publication URI: http://europepmc.org/abstract/MED/35863669

Type: Journal Article/Review

Volume: 10

Parent Publication: The journal of allergy and clinical immunology. In practice

Issue: 11